LB Pharmaceuticals Inc (LBRX)

Market Cap	556.07M
Revenue (ttm)	n/a
Net Income (ttm)	-18.80M
Shares Out	25.30M
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	339,461
Open	22.20
Previous Close	22.50
Day's Range	20.22 - 22.93
52-Week Range	13.36 - 23.15
Beta	n/a
Analysts	Strong Buy
Price Target	46.33 (+110.78%)
Earnings Date	Nov 6, 2025

About LBRX

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 11, 2025
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: LBRX
• Website: https://lbpharma.us

Analyst Summary

According to 3 analysts, the average rating for LBRX stock is "Strong Buy." The 12-month stock price target is $46.33, which is an increase of 110.78% from the latest price.

Price Target

$46.33

(110.78% upside)

Analyst Consensus: Strong Buy